Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
| Market Cap | 843.97M+36.7% |
| Revenue (ttm) | 41.47M-29.0% |
| Net Income | -61.12M+49.3% |
| EPS | -0.15+54.6% |
| Shares Out | 444.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,880,289 |
| Open | 1.86 |
| Previous Close | 1.79 |
| Day's Range | 1.81 - 2.05 |
| 52-Week Range | 1.10 - 2.68 |
| Beta | 1.03 |
| Analysts | Hold |
| Price Target | 6.00(+215.79%) |
| Earnings Date | Nov 5, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
$LXRX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in LXRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LXRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LXRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LXRX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Interest and other income | $1.72M | 55.46% |
| License | $692.00K | 22.27% |
| Net product and licensing revenue | $680.00K | 21.89% |
| Royalties and other revenue | $12.00K | 0.39% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LXRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LXRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LXRX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $15.94M |
| IWMiShares Russell 2000 ETF | $10.85M |
| VXFVanguard Extended Market ETF | $5.91M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $4.21M |
| IWOiShares Russell 2000 Growth ETF | $4.00M |
| VTWOVanguard Russell 2000 ETF | $3.22M |
Estimated from each fund’s disclosed top holdings × AUM
LXRX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LXRX’s recent data — informational, not investment advice